Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Change in Accured Expenses: 2011-2025

Historic Change in Accured Expenses for Aytu Biopharma (AYTU) over the last 15 years, with Jun 2025 value amounting to $886,000.

  • Aytu Biopharma's Change in Accured Expenses rose 67.06% to -$1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year increase of 145.34%. This contributed to the annual value of $886,000 for FY2025, which is 109.67% up from last year.
  • Latest data reveals that Aytu Biopharma reported Change in Accured Expenses of $886,000 as of FY2025, which was up 109.67% from -$9.2 million recorded in FY2024.
  • In the past 5 years, Aytu Biopharma's Change in Accured Expenses registered a high of $3.6 million during FY2023, and its lowest value of -$13.3 million during FY2022.
  • Its 3-year average for Change in Accured Expenses is -$1.6 million, with a median of $886,000 in 2025.
  • As far as peak fluctuations go, Aytu Biopharma's Change in Accured Expenses plummeted by 1,823.99% in 2022, and later skyrocketed by 127.12% in 2023.
  • Over the past 5 years, Aytu Biopharma's Change in Accured Expenses (Yearly) stood at $771,000 in 2021, then slumped by 1,823.99% to -$13.3 million in 2022, then skyrocketed by 127.12% to $3.6 million in 2023, then crashed by 354.12% to -$9.2 million in 2024, then spiked by 109.67% to $886,000 in 2025.